Sign in
Taking peopleNo phase

Spinocerebellar Ataxia Type 27B Natural History Study (SCA27B-NHS)

Key facts

Who runs it
University Hospital Tuebingen
Where
Czechia, Germany, Italy, and Spain5 sites in 4 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
300 people, planned
Started
4 Jun 2024
Expected to end
31 Dec 2028
Type of study
Observational, 3 groups
Record updated
6 April 2026

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • SCA27B: genetic diagnosis of ≥250 uninterrupted GAA repeat expansions in FGF14
  • SCA27B risk subject: asymptomatic first-degree relative of SCA27B participant with known or unknown carrier status
  • Unrelated healthy controls: no signs or history of neurological or psychiatric disease AND
  • Written informed consent AND
  • Participants are willing and able to comply with study procedures

Who cannot take part

  • Unrelated healthy controls: Missing informed consent, or concurrent neurological, orthopedic, or other diseases interfering with the motor assessments
  • SCA27B: Missing informed consent
  • SCA27B risk subjects: Missing informed consent

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

This trial has no sites in United States.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This international, multi-center, multi-modal, and prospective observational cohort study aims to validate trial outcomes for capturing disease progression in Spinocerebellar Ataxia Type 27B (SCA27B), with combined multi-modal capture of clinical outcome assessments, digital-motor assessments, and molecular biomarkers.

The 3 groups in the trial

  • SCA27B

    Participants with genetically confirmed SCA27B (OMIM 620174), i.e. ≥250 uninterrupted GAA repeat expansions in FGF14, will be recruited. Target sample size for the SCA27B cohort is 200 participants.

  • SCA27B risk subjects

    First-degree relatives at risk for SCA27B, both with known and unknown carrier status, will be included to capture presymptomatic disease stages. Target sample size for the risk cohort is 50 participants

  • Unrelated healthy controls

    Unrelated healthy controls may undergo the same study procedures as the SCA27B cohort to determine age-related effects on the multimodal outcomes. Target sample size for the control cohort is 50.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06472557, who can take part
Record updated
6 April 2026